Related references
Note: Only part of the references are listed.The EMPA-REG outcome study: critical appraisal and potential clinical implications
Gianluca Perseghin et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
Karen S. L. Lam et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies
Raktim Kumar Ghosh et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
Alan J. Sinclair et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2016)
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Deepson S Shyangdan et al.
BMJ Open (2016)
Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
Takashi Sasaki et al.
ADVANCES IN THERAPY (2015)
Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
Hiroaki Iijima et al.
ADVANCES IN THERAPY (2015)
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
Norm Rosenthal et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014 (2015)
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside
Sunder Mudaliar et al.
DIABETES CARE (2015)
Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study
Nobuya Inagaki et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure
Tetsushiro Takeuchi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
Jochen Seufert
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents
Takahiro Oguma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
A mathematical model of the rat nephron: glucose transport
Alan M. Weinstein
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Greg L. Plosker
DRUGS (2014)
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Steven E. Kahn et al.
LANCET (2014)
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes (vol 9, e105638, 2014)
S. Sha et al.
PLOS ONE (2014)
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
Yoshihito Fujita et al.
JOURNAL OF DIABETES INVESTIGATION (2014)
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Daniel Lorber
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2014)
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion Results of a randomized, placebo-controlled study
David Polidori et al.
DIABETES CARE (2013)
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury
Jarkko Piuhola et al.
CLINICAL SCIENCE (2008)
Share Paper
